

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38602/183

Applicant: Axel ULLRICH et al.

Appl. No.: 09/286,641

Filing Date: April 2, 1999

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

Title: FLK-1 IS A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH FACTOR

**REVOCATION OF PRIOR POWERS OF ATTORNEY AND
APPOINTMENT OF NEW POWER OF ATTORNEY BY ASSIGNEE
CHANGE OF CORRESPONDENCE ADDRESS**

Commissioner for Patents
Washington, D.C. 20231

Sir:

MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
is the ASSIGNEE of Application No. 08/193,829, filed February 9, 1994, and all
continuing applications thereof, as evidenced by an Assignment recorded in the U.S.
Patent and Trademark Office on June 23, 1994 at reel/frame 7033/0720.

MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
through its duly-delegated representative, hereby revokes all prior Powers of Attorney
submitted in this application, and hereby appoints the following registered attorneys and
agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT	Reg. No. 29,768
DAVID A. BLUMENTHAL	Reg. No. 26,257
BETH A. BURROUS	Reg. No. 35,087
ALAN I. CANTOR	Reg. No. 28,163
WILLIAM T. ELLIS	Reg. No. 26,874
JOHN J. FELDHAUS	Reg. No. 28,822
MICHAEL D. KAMINSKI	Reg. No. 32,904
LYLE K. KIMMIS	Reg. No. 34,079
KENNETH E. KROGIN	Reg. No. 25,735

Atty. Dkt. No. 38602/275

JOHNNY A. KUMAR	Reg. No. 34,649
GLENN LAW	Reg. No. 34,371
PETER G. MACK	Reg. No. 28,601
STEPHEN B. MAEBIUS	Reg. No. 35,264
BRIAN J. MC NAMARA	Reg. No. 32,789
SYBIL MELOY	Reg. No. 22,749
RICHARD C. PEET	Reg. No. 35,792
GEORGE E. QUILLIN	Reg. No. 32,792
ANDREW E. RAWLINS	Reg. No. 34,702
BERNHARD D. SAXE	Reg. No. 29,665
CHARLES F. SCHILL	Reg. No. 27,590
RICHARD L. SCHWAAB	Reg. No. 25,479
ARTHUR SCHWARTZ	Reg. No. 22,115
MICHELE SIMKIN	Reg. No. 34,717
HAROLD C. WEGNER	Reg. No. 25,258

and the following additional attorney: H. Thomas Anderton, Jr., Reg. No. 40,895, and Rekha Bansal, Reg. No. 38,440; as its principal attorneys to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, to transact all business in the United States Patent and Trademark Office connected therewith, and to have full power of substitution, association, and revocation, including the power to revoke the power of attorney of any associate attorney.

Assignee understands and agrees that the foregoing attorneys and agents appointed by Assignee to prosecute this application do not generally represent the Assignee or its legal interests, but instead are being appointed for the limited purpose of prosecuting this patent application, as described above.

Please direct all future correspondence concerning this application to:


Beth A. Burrous
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109

Telephone: (202) 672-6300
Facsimile: (202) 672-5399

Atty. Dkt. No. 39602/275

Executed this 9th day of March, 2001.MAX-PLANCK-GESELLSCHAFT ZUR
FOERDERUNG DER WISSENSCHAFTEN E.V.:

By:


(Signature)Ms Christa Herzog

(Printed Name)

Head of patent department

(Title)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 38602/183

Applicant: Axel ULLRICH et al.

Appl. No.: 09/286,641

Filing Date: April 2, 1999

Examiner: Not Yet Assigned

Art Unit: Not Yet Assigned

Title: FLK-1 IS A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH FACTOR

**REVOCATION OF PRIOR POWERS OF ATTORNEY AND
APPOINTMENT OF NEW POWER OF ATTORNEY BY ASSIGNEE
CHANGE OF CORRESPONDENCE ADDRESS**

Commissioner for Patents
Washington, D.C. 20231

Sir:

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM is the ASSIGNEE of Application No. 08/193,829, filed February 9, 1994, and all continuing applications thereof, as evidenced by an Assignment recorded in the U.S. Patent and Trademark Office on June 23, 1994 at reel/frame 7038/0807.

YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM through its duly-delegated representative, hereby revokes all prior Powers of Attorney submitted in this application, and hereby appoints the following registered attorneys and agents of the law firm of FOLEY & LARDNER:

STEPHEN A. BENT	Reg. No. 29,768
DAVID A. BLUMENTHAL	Reg. No. 28,257
BETH A. BURROS	Reg. No. 36,097
ALAN I. CANTOR	Reg. No. 28,153
WILLIAM T. ELIIS	Reg. No. 28,874
JOHN J. FELDHAUS	Reg. No. 28,822
MICHAEL D. KAMINSKI	Reg. No. 32,904
LYLE K. KIMMS	Reg. No. 34,079
KENNETH E. KROGIN	Reg. No. 25,735

JOHNNY A. KUMAR	Reg. No. 34,649
GLENN LAW	Reg. No. 34,371
PETER G. MACK	Reg. No. 26,001
STEPHEN B. MAEBIUS	Reg. No. 35,264
BRIAN J. MC NAMARA	Reg. No. 32,789
SYBIL MELOY	Reg. No. 22,748
RICHARD C. PEET	Reg. No. 35,792
GEORGE E. QUILLIN	Reg. No. 32,792
ANDREW E. RAWLINS	Reg. No. 34,702
BERNHARD D. SAXE	Reg. No. 28,865
CHARLES F. SCHILL	Reg. No. 27,590
RICHARD L. SCHWAAB	Reg. No. 28,479
ARTHUR SCHWARTZ	Reg. No. 22,115
MICHELE SIMKIN	Reg. No. 34,717
HAROLD C. WEGNER	Reg. No. 28,258

and the following additional attorney: H. Thomas Anderton, Jr., Reg. No. 40,895, and Rekha Bansal, Reg. No. 38,440; as its principal attorneys to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, to transact all business in the United States Patent and Trademark Office connected therewith, and to have full power of substitution, association, and revocation, including the power to revoke the power of attorney of any associate attorney.

Assignee understands and agrees that the foregoing attorneys and agents appointed by Assignee to prosecute this application do not generally represent the Assignee or its legal interests, but instead are being appointed for the limited purpose of prosecuting this patent application, as described above.

Please direct all future correspondence concerning this application to:

Beth A. Burrous
FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109

Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Executed this 26th day of March, 2001.

YISSUM RESEARCH DEVELOPMENT COMPANY OF
THE HEBREW UNIVERSITY OF JERUSALEM:

By:

YISSUM
RESEARCH DEVELOPMENT COMPANY
OF THE
HEBREW UNIVERSITY OF JERUSALEM

Avi Barak
(Signature)

Abraham Barak
Managing Director & CEO

(Title)